Patent · US Active

2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

US10774070B2 · kind B2 · utility

4Cited by

27References

14Claims

0Family size

Assignee

Blueprint Medicines Corporation · US

Inventors

Natasja Brooijmans · Boston, US
Lucian V. DiPietro · Gloucester, US
Paul E. Fleming · Wellesley, US
Joseph L. Kim · Wayland, US
Steven Mark Wenglowsky · Boulder, US
Yulian Zhang · San Diego, US

Key dates

Filing date	Dec 20, 2018
Grant date	Sep 15, 2020
Priority date	—
Expiry date	Dec 20, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g., for treating a condition mediated by aberrant RET activity

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.